Helsinki- and Cambridge, Massachusetts-based Switchpoint Bio has raised $5.3 million (€4.75 million) in pre-seed financing—marking the TechBio startup's first funding round after emerging from stealth in 2025. The round was led by Treehouse Delmar Investments, which contributed $5 million (€4.48 million) of the total capital. Founded by a five-member team including Blueprint Genetics co-founder Samuel Myllykangas and ATAC-seq inventor Jason Buenrostro, the company will use the proceeds to advance its AI-powered, blood-based epigenomic platform. Specifically, the capital will accelerate development of its targeted DNA methylation profiling assay designed to help drug developers monitor disease changes, treatment response, and drug resistance from routine blood samples.
